This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 Results: Revenue up 19% YoY, PAT up 5%; Saudi plant approved
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Rossari Biotech posted consolidated Q2 FY27 revenue of Rs 6,975.60 million, up 19% YoY from Rs 5,861.07 million. PAT rose 5.5% to Rs 389.07 million. H1 FY27 revenue grew 23.4% to Rs 13,947.60 million; PAT up 5% to Rs 740.02 million. Standalone H1 revenue grew 24.5% to Rs 9,775.51 million. Board approved land lease in Saudi Arabia for a new greenfield plant by wholly owned subsidiary Rossari International.
Strong top-line growth across segments; modest PAT growth. Expansion into Saudi Arabia signals a growth push. Watch margin trends.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹697.6 Cr | ₹586.1 Cr | +19.0% |
| Operating profit | ₹48.20 Cr | ₹47.60 Cr | +1.3% |
| Profit after tax | ₹38.91 Cr | ₹36.88 Cr | +5.5% |
| EBITDA margin | 12.5% | 12.3% | +0.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.